Unichem Laboratories Limited
NSE: UNICHEMLAB · Pharmaceuticals
Snapshot
Unlock Unichem Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Unichem Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of finished formulations and active pharmaceutical ingredients. The company operates across diverse therapeutic segments including gastroenterology, cardiology, and neurology, while also providing contract manufacturing services globally.
Business Model
The company generates revenue through the sale of branded and generic pharmaceutical formulations, the supply of active pharmaceutical ingredients, and the provision of contract manufacturing services to third-party clients.
- Founded:1944
Growth Outlook
Growth is driven by the expansion of its therapeutic product portfolio and the leveraging of its contract manufacturing capabilities to capture global market demand.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical market can lead to significant price erosion and margin compression.
- Supply Chain Volatility. Dependence on external suppliers for raw materials and active pharmaceutical ingredients exposes the company to potential supply chain disruptions.
- Currency Fluctuation. As a global exporter, the company is susceptible to volatility in foreign exchange rates which may impact profitability.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Unichem Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,202 Cr
TTM · consolidated
NET PROFIT
₹253 Cr
TTM · consolidated
EPS
₹35.91
TTM · consolidated
RETURN ON EQUITY
10.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
12.2%
TTM · consolidated
P/E
16.8x
Q4 FY26 · consolidated
EV/EBITDA
18.2x
Q4 FY26 · consolidated
EBITDA MARGIN
11.1%
TTM · consolidated
NET PROFIT MARGIN
1.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Unichem Laboratories LimitedUNICHEMLAB | 2,111 | 16.84 | 18.17 | 8.5% | 11.1% | 10.0% | 12.2% | -6.3% |
Novartis IndiaNOVARTIND | 2,266 | 42.28 | 29.45 | -0.5% | 37.5% | 11.7% | 16.1% | +51.3% |
Bliss GVS PharmaBLISSGVS | 2,193 | 41.29 | 22.41 | 14.5% | 25.6% | 12.4% | 17.4% | +219.3% |
Panacea BiotecPANACEABIO | 2,027 | -640.85 | 279.46 | 14.4% | 1.9% | -0.9% | -0.1% | +30.3% |
Morepen Labs.MOREPENLAB | 2,011 | 35.16 | 23.79 | -0.3% | 8.1% | 8.0% | 10.3% | -3.9% |
HikalHIKAL | 1,988 | -207.43 | 15.31 | -7.9% | 13.6% | -3.9% | -0.9% | -32.4% |
As of Q4 FY26
Financials
Unichem Laboratories Limited
NSE: UNICHEMLAB · Pharmaceuticals
Snapshot
Unlock Unichem Laboratories Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Unichem Laboratories Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of finished formulations and active pharmaceutical ingredients. The company operates across diverse therapeutic segments including gastroenterology, cardiology, and neurology, while also providing contract manufacturing services globally.
Business Model
The company generates revenue through the sale of branded and generic pharmaceutical formulations, the supply of active pharmaceutical ingredients, and the provision of contract manufacturing services to third-party clients.
- Founded:1944
Growth Outlook
Growth is driven by the expansion of its therapeutic product portfolio and the leveraging of its contract manufacturing capabilities to capture global market demand.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical market can lead to significant price erosion and margin compression.
- Supply Chain Volatility. Dependence on external suppliers for raw materials and active pharmaceutical ingredients exposes the company to potential supply chain disruptions.
- Currency Fluctuation. As a global exporter, the company is susceptible to volatility in foreign exchange rates which may impact profitability.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Unichem Laboratories Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,202 Cr
TTM · consolidated
NET PROFIT
₹253 Cr
TTM · consolidated
EPS
₹35.91
TTM · consolidated
RETURN ON EQUITY
10.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
12.2%
TTM · consolidated
P/E
16.8x
Q4 FY26 · consolidated
EV/EBITDA
18.2x
Q4 FY26 · consolidated
EBITDA MARGIN
11.1%
TTM · consolidated
NET PROFIT MARGIN
1.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26